Table Of Content

Subject Index A staging dietary patterns to reduce diabetes hyperglycemic crisis in diabetes mellitus, risk in, 809 $100 A Diabetes Outcome Progression Trial with type 2 diabetes, physical activity hypoglycemia and employmenv/icensure, (ADOPT), 1737 intervention for, 1576 $132 Abdomen, alternative-site blood glucose Age, maternal, and insulin resistance in twins, immunization and prevention of influenza measurement at, 2114 2191 and pneumococcal disease in Abdominal fat Air pollution, diabetes and, 1487, 2367 diabetes, $117 combination diet and voglibose or glyburide Alaska Natives insulin administration, $112 and, in type 2 diabetes, 658 cardiovascular disease risk factors in, 279 laboratory analysis in diagnosis and weight loss and, in obese women, 431 HbA, < levels in, 2178 management of diabetes mellitus, 750 Aborigines Albumin management of diabetes at diabetes camps, women, gestational diabetes in, 487 youth with type 2 diabetes, HNF-la G319S Amadori, and complications of type 1 $127 mutation in, 2202 diabetes, 2320 management of diabetes in correctional Abuse, childhood, 801 urinary excretion, and carotid intima-media institutions, $120 Acanthosis nigricans thickness, in type 2 diabetes, 936 management of dyslipidemia in adults in Cherokee Indians, 1009 Albumin excretion rate with diabetes, $74 and insulin resistance in obesity, in children, irbesartan and, in type 2 diabetes, 1909 pancreas transplantation for type | 2353 white blood cells and, in type 2 diabetes, diabetes, $111 Activated protein C, plasma TAFI levels and, in 2354 preconception care of women with type 2 diabetes, 1245 Albuminuria, in recent-onset type 2 diabetes, diabetes, S82 Acute intermittent porphyria, diabetes effects 1078 prevention of type | diabetes mellitus, on, 797 Alcohol consumption $131 Adherence, and HbA,,- levels, 731 and atherosclerotic risk, in type 2 diabetes, prevention or delay of type 2 diabetes, Adipoinsular axis, dysregulation of, fetal 1223 742, 947 overnutrition and, in Polynesians, 1539 and carotid atherosclerosis, insulin sensitivity preventive foot care in diabetes, S69 Adiponectin and, 1425 screening for diabetes, S21 plasma levels, rosiglitazone and, in type 2 Alkali therapy, in severe diabetic ketoacidosis, smoking and diabetes, S80 diabetes, 376 2113 standards of care for diabetes, 213, $33 serum levels Allergy, to human insulin, continuous tests of glycemia in diabetes, S97 in high normal blood pressure, 971 subcutaneous insulin infusion for, 634 third-party reimbursement for diabetes in type | diabetes, 1665 Allografts, bone marrow, type 1 diabetes care, self-management education, and Adiposity transmission by, 799 supplies, $134 different racial groups, 2360 Alveolar-capillary membrane gas conductance, translation of the diabetes nutrition symposium, 2342 insulin effects on, in type 2 diabetes, 1802 recommendations for health care Adiposity-related diabetes risk, reduction by Amadori albumin, and complications of type 1 institutions, S61 lifestyle modification, in Japanese diabetes, 2320 treatment of hypertension in adults with Americans with impaired glucose American Association of Clinical diabetes, 199, S71 tolerance, 1504 Endocrinologists meeting, May 2002, United Kingdom Prospective Diabetes Adminiisntcriadteincvee fdartoam,, diina bOentteasr iop,r ev5a1l2e nce and trea1t4m6e4n t of type 2 diabetes, 1644 unproSvteund y thiemrpalpiiceast,i on$s1,3 3 $21 Adolescent diabetes American Diabetes Association (ADA) research funded by, year 3 status, 626 type | Annual Meeting 61st Scientific Sessions personal control and disordered eating in diabetes and nutrition, 1869 epidemiology of complications, 924 tphryerdoiciftdeo mraaslu etsoo fi wsmiymtuhm,np itt1oy9m8 7i dn,e te1c3t4i6o n in, 852 obesitrye,s ihstyapnecret,e n2s0io8n8, and insulin ntreeuartomspeoancttih yo,eof c owtnyoopmmee inc1’ sda isaphbeeecattlests,h, , 12a03n80d5 TPS serum levels in, 240 classification for diabetes, 951 treatment of type 2 diabetes, 390, 614 weight control behaviors among, 1289 Dietary Guidelines, 1262 standards of care, adherence to, by rural type 2, blood pressure profiles in, 2354 Expert Committee on the Diagnosis and health care providers, 2224 Adolescent diabetis dwarfism, GERD and Classification of Diabetes Mellitus summary of revisions for 2002 clinical progressive nephropathy after glycemic report, S5 practice recommendations, $3 control improvement in, 401 guidelines, adherence to, in pharmacist- American Indians Adolescents, postprandial hyperglycemia in, managed diabetes clinics, 1479 cardiovascular disease risk factors in, 279 1887 position statements diabetes incidence in, +9 Adult-onset diabetes aspirin therapy in diabetes, $78 HbA, . levels in, 2178 dyslipidemia management in, ADA position bedside blood glucose monitoring in metabolic syndrome in, 1246 statement, S74 hospitals, $110 postmenopausal women, estrogen effects on with GAD autoantibodies care of children with diabetes in school glucose, insulin, and type 2 diabetes risk clinical heterogeneity of, 2363 and day care setting, $122 in, 500 in Japan, 2364 concurrent care, $130 screening for type 2 diabetes in, fasting in Japan, 995 continuous subcutaneous insulin infusion, plasma glucose plus HbA,,. for, 1365 Advanced glycation end products, and $116 American Society of Hypertension (ASH) endothelial dysfunction, 1055 Diabetes Control and Complications Trial Annual Meeting, obesity, hypertension, Aerodose Insulin Inhaler, dose reproducibility (DCCT) implications, $21 and insulin resistance, 2088 of, in type 2 diabetes, 2276 diabetes mellitus and exercise, S64 Amputation, lower limb, in type 2 diabetes, in African-Americans diabetic nephropathy, $85 Dutch primary health care, 570 children, insulin resistance in, 2184, 2350 diabetic retinopathy, $90 Amylin, co-release of insulin and, in first-degree diabetes incidence in, fiber intake and evidence-based nutrition for diabetes relatives, 292 glycemic index and, 1715 treatment and prevention, 202, 1263, Angioneurotic edema, with pioglitazone, 405 fasting serum insulin in, 1358 $50 Angiotensin-converting enzyme gene urban, outpatient management and serum gestational diabetes mellitus, S94 polymorphism, and metabolic syndrome lipids in, 9 hospital admission guidelines for diabetes in Brazilian type 2 diabetes, 2365 women mellitus, $109 in Chinese type 2 diabetes, 1002, 2366 2002 SUBJECT INDEX Angiotensin-converting enzyme inhibitors, for in Japan, 995 frequency of, and glycemic control, in type 2 diabetes with hypertension, 1488 type 1 diabetes-associated, dietary gluten diabetes, 245 Animal protein, for type 2 diabetes, 1277 and, in high-risk subjects, 1111 noninvasive, 2268 Anorexia nervosa, with type | diabetes, Autoimmune diabetes, latent, insulin with optical coherence tomography, 2263 mortality in, 309, 800, 1664 requirements, 1662 Blood glucose self-monitoring Antibodies. see also Autoantibodies Autoimmune-related type 1 diabetes, costs of, 1244 GAD mitochondrial genotype associated with, evaluation of, 1603 in mitochondrial diabetes associated with 2106 meal-related, in type 2 diabetes, 1928 tRNA mutation, 1097 Autoimmunity in pregnancy, 2104 screening for, in gestational diabetes, 68 fulminant type | diabetes with, 1482 strategies for, in type 2 diabetes, 1744 1A-2, cyclosporin and, in type 1 diabetes, T-cell—mediated, in fulminant type 1 value of, 1255 1192 diabetes, 635 Blood letting, in high-ferritin type 2 diabetes, TSH receptor, fulminant type | diabetes thyroid, in children and adolescents with 2249 with, 935 type | diabetes, 1346 Blood pressure Anticonvulsant hypersensitivity syndrome, with Autonomic nervous system, cardiac, in adolescent type 2 diabetes, 2354 eosinophilia, in treatment of diabetic dysfunction in mitochondrial diabetes, central, insulin effects on, in type 2 diabetes, neuropathy, 1099 2308 2314 Antidiabetic agents, oral, a-glucosidase Autonomic neuropathy, sympathetic, pupil high normal, serum adiponectin levels in, inhibitor interactions, 247 signs of, in type | diabetes, 1545 971 Antihypertensive therapy, prevalence of, in home measurement of, in morning, in type 2 diabetes, 2107 diabetes, 2218 Antwerp (Belgium), incidence of type | and retinopathy, 1320 diabetes in, 840 Beaver Dam (Wisconsin), metabolic syndrome Blood-retinal barrier, transport across, in Anxiety, among partners of patients with type 2 and cardiovascular disease risk in, 1790 macular edema, in type 2 diabetes, 1248 diabetes, 1564 Bedside blood glucose monitoring, in hospitals, Body composition, improvement by lifestyle Apolipoprotein(a), and silent coronary disease ADA position statement, $110 modification, in Japanese Americans with in type 2 diabetes, 1418 Bedtime NPH insulin, combined with impaired glucose tolerance, 1504 Apolipoprotein B, hypertriglyceridemic repaglinide vs metformin, in type 2 Body fat distribution, improvement by lifestyle hyperapoB, in type 2 diabetes, 579 diabetes, 1685 modification, in Japanese Americans with Arm, capillary glucose and Het of, 337 Behavior impaired glucose tolerance, 1504 Arm glucose monitoring, 956 body mass index correlates, in DPP, 1992 Body mass index hypoglycemia detection by, 639 eating, among adolescents with type | ethnicity and, 1351 Aspirin therapy diabetes, 1289 improvement by lifestyle modification, in ADA position statement, $78 mealtime, in young children with type 1 Japanese Americans with impaired in diabetes, 965 diabetes, 313 glucose tolerance, 1504 Asthma, pioglitazone for, 401 purging, classification of type 1 diabetes with maternal, and insulin resistance in twins, Atherosclerosis bulimia nervosa according to, 1571 2191 alcohol consumption and, in type 2 diabetes, weight control, among adolescents with type psychological and behavioral correlates, in 1223 1 diabetes, 1289 DPP, 1992 carotid Behavioral science, in prevention of diabetes, Body weight, diabetic breast-milk and, 16 alcohol consumption and, insulin 599 Bone marrow allografts, type 1 diabetes sensitivity and, 1425 Belgium transmission by, 799 C-reactive protein and, in type | diabetes, incidence of type 1 diabetes in, 840 Brachial artery flow-mediated dilatation, 1432 newly diagnosed type 2 diabetic population sildenafil and, in type 2 diabetes, 1336 coronary in, 637 Brainstem, auditory, functional impairment in pancreas transplantation and, 906 B-cell function, insulin sensitivity and, in diabetic neuropathy, 631 subclinical, in type 2 diabetes, 1313 polycystic ovary syndrome, 1217 Brazilians Atherosclerosis Risk in Communities (ARIC) Biceps tendon, thickness of, in diabetes, 408 IRS-1 Gly972Arg polymorphism and birth Study Birth weight weight in, 550 fiber intake, glycemic index, and diabetes and diabetes risk, 1886 with type 2 diabetes, ACE gene incidence, 1715 IRS-1 Gly972Arg polymorphism and, in polymorphism and metabolic syndrome insulin, race, and type 2 diabetes incidence, Brazilian newborns, 550 in, 2365 1358 maternal, gestational diabetes and, 1761 Breast milk, diabetic, effects on body weight Atopic symptoms, and childhood type | Blood flow, postischemic microcirculatory, and and glucose in children, 16 diabetes, 865 plasma C-reactive protein, in type 1 Brittle diabetes, continuous subcutaneous Atorvastatin diabetes, 802 insulin infusion therapy for, long-term combined with fenofibrate, in type 2 Blood fructose, increased levels, 353 follow-up, in elderly, 402 diabetes, 1198 Blood glucose Bulimia nervosa, with type | diabetes, effects on cognitive function and diabetic distribution of, bimodality of, 2212 classification according to purging, 1571 dyslipidemia, 1250 maternal levels, third-trimester, in effects on endothelial function, in type 2 nondiabetic pregnancies, 939, 1104 C diabetes, 1211 variability in type 1 diabetes, 2256 Caffeine Attachment theory, and HbA,.. levels, 731 Blood glucose monitoring and insulin resistance, 399 Auditory brainstem, functional impairment of, alternative-site, at abdomen, 2114 and insulin sensitivity, 364 in diabetic neuropathy, 631 barriers to, in multiethnic community, 1772 Caiapo. see Ipomoea batatas Australian Diabetes, Obesity and Lifestyle bedside, in hospitals, ADA position Calcium, coronary, in diabetes, 696 Study, prevalence of diabetes and impaired statement, $110 Canada glucose tolerance, 829 continuous Aboriginal population Autoantibodies evaluation of, 1603 gestational diabetes in women, 487 childhood diabetes prediction through, 505 glucose area under profiles obtained with, HNF-1la G319S mutation in youth with GAD, adult-onset diabetes with and HbA, ¢, in pediatric type 1 type 2 diabetes, 2202 clinical heterogeneity of, 2363 diabetes, 1840 diabetes care in, 1149 in Japan, 2364 vs intermittent, 1603 diabetes costs in, 1303 2002 SUBJECT INDEX Ontario Chicken-based diet, and microalbuminuria, in Collagen, oxidized regenerated cellulose diabetes prevalence and incidence in, from type 2 diabetes, 645 composite, for diabetic foot ulcers, 1892 administrative data, 512 Childhood abuse, and diabetes, 801 Co-management care, 1657 hospitalization of children with diabetic Childhood diabetes Community interventions, diabetes care, 941 ketoacidosis in, 1591 abuse and, 801 Community-based diabetes care, Mayo Health Capillary glucose care in school and day care setting, ADA System Diabetes Translation Project, 1952 differences at finger, forearm, and thigh, 961 position statement, $122 Complementary and alterriative medicine from fingertip and forearm, 337 type | prevalence and pattern of use by individuals Captopril, for diabetes with hypertension, 1488 atopic symptoms and, 865 with diabetes, 324 Carbohydrate metabolism, during pregnancy, cerebrovascular reactivity in, 409 risks, 411 560 comorbidity of anorexia nervosa and, 800 Computer-generated personalized goals, and CARDIA Study, oral contraceptive use and drinking water and, 1534 HbA, 2 glucose and insulin in young adult early growth and, in European Concurrent care, ADA position statement, $1 30 women, 1027 populations, 1755 Consensus statements, $139 Cardiac events, after screening for CHD, in type epidemiology in Philadelphia, 1969 Continuous enteric tube feeding, insulin 2 diabetes, 2032 fulminant-onset idiopathic, with insulin glargine in, 1889 Cardiac ischemia, Q-T interval dispersion and, deficiency, 2353 Continuous glucose monitoring, 1185 in type | diabetes, 702 glucose area under CGMS profiles and evaluation of, 1603 Cardiac neuropathy HbA, in, 1840 subcutaneous, 347 in mitochondrial diabetes, 2308 incidence in Denmark, 2197 Continuous glucose monitoring system (CGMS) ventricular repolarization and, 918 lipohypertrophy in, 634 (Medtronic MiniMed) Cardiorespiratory fitness, and metabolic mealtime behavior and parenting stress in, glucose area under profiles obtained with, syndrome, 1612 313 and HbA,,,, in pediatric type 1 diabetes, Cardiovascular disease prediction through multiple defined 1840 cost impact of, 482 autoantibodies, 505 nocturnal hypoglycemia recording by, in type insulin resistance and, 1135, 1177 thyroid autoimmunity in, 1346 1 diabetes, 1499 insulin sensitivity and alcohol consumption TPS serum levels in, 240 Continuous subcutaneous insulin infusion and, 1425 VDR genotype and age of onset in, in ADA position statement, $116 prediction of, 1851 Japanese, 1244 for allergy io human insulin, 634 vitamin E effects on, in diabetes, 1919 type 2, metformin effects in, 89 evidence base for, 593 Cardiovascular mortality Children indications for, 2100 in diabetes, 1557 with diabetic ketoacidosis, hospitalization of, insulin aspart in, for type 1 diabetes, 439 diabetes and, in Japanese-American men, 951 in Ontario, 1591 long-term follow-up, in brittle diabetic with metformin, in type 2 diabetes, 2244 of diabetic mothers, diabetic breast milk elderly, 402 Cardiovascular risk effects on body weight and glucose in, metformin therapy during, in type | diabetes, fasting and postchallenge glycemia and, 1845 16 2153 metabolic syndrome and, in Beaver Dam, fasting indices of insulin action in, 2081 in type | diabetes, 2074 1790 HbA, . levels in, in U.S., 1326 Corn oil supplementation, and lipoprotein prior to type 2 diabetes diagnosis, 1129 insulin pump use by, 1663 subclasses, in type 2 diabetes, 1704 Cardiovascular risk factors insulin resistance in, El Coronary artery calcification, 696 in American Indians and Alaska Natives, 279 in African-Americans and Hispanics, 2184, C-reactive protein and, in type | diabetes, control of, in diabetes and hypertension, 718 2350 1813 metformin and troglitazone effects on, in type insulin sensitivity in, prediction of, 1203 Coronary artery disease 2 diabetes, 542, 947 with obesity, acanthosis nigricans and insulin asymptomatic, Lp(a) and, in type 2 diabetes, Cardiovascular risk profile, of patients resistance in, 2353 1418 identified by screening for diabetes, 1784 Chinese dobutamine stress echocardiography Cardiovascular system, rosiglitazone vs with type 2 diabetes, ACE gene detection of, in type 2 diabetes, 1659 glyburide effects on, in type 2 diabetes, polymorphism and metabolic syndrome intima-media thickness and, in type 2 2058 in, 1002, 2366 diabetes, 1308 Carotid atherosclerosis women mortality in, prediction with stress C-reactive protein and, in type | diabetes, gestational diabetes in echocardiography, in diabetes, 1042 1432 screening for, 796 pancreas transplantation and, 906 insulin sensitivity and alcohol consumption in Tianjin City, 847 Coronary Artery Risk Development in Young and, 1425 impaired glucose tolerance during Adults (CARDIA) Study, neighborhoods Carotid intima-media thickness, in type 2 pregnancy in, in Tianjin City, 1619 and insulin resistance, 1976 diabetes Cholesterol Coronary atherosclerosis, subclinical, in type 2 and coronary artery disease, 1308 HDL, direct measurement of, in diabetes, diabetes, 1313 IGFBP-1 and, 1807 1914 Coronary calcium, in diabetes, 696 and urinary albumin excretion, 936 metabolism of, diabetes and, 1511 Coronary heart disease Carpal tunnel syndrome, in diabetic remnant, in diabetes, 989 obesity and, in diabetic women, 1142 polyneuropathy, 565, 2362 serum, caiapo and, in type 2 diabetes, 239 screening for, cardiac events after, in type 2 Carpenter and Coustan plasma glucose Cigarette smoking diabetes, 2032 thresholds, prevalence of gestational and glycemic control, in diabetes, 796 Coronary heart disease risk factors, wheat bran diabetes by, 1625 and tubulointerstitial lesions in type 2 and, in type 2 diabetes, 1522 Celiac disease, gluten-free diet and glycemic diabetes, 1486 Coronary stenosis, diabetes and, 696 control in type 1 diabetes with, 1117 Clarithromycin, sulfonylurea interactions, 1659 Correctional institutions, management of Cellulose, oxidized regenerated, collagen Clinical Scoring System (CSS), validation of, diabetes in, ADA position statement, $120 composite, for diabetic foot ulcers, 1892 2048 Cost-benefit analysis Cerebrovascular reactivity, in type 1 diabetic Clinical trials, evaluation of liver function in of cardiovascular disease, +82 children, 409 type 2 diabetes during, 815 of diabetes, 23 Cherokee Diabetes Study, acanthosis nigricans Cockcroft’s formula, for GFR estimation, in in Canada, 1303 in Cherokee Indians, 1009 lipid-lowering drug-treated diabetes, 2106 of HMO-sponsored diabetes disease Cherokee Indians, acanthosis nigricans in, 1009 Cognitive function, atorvastatin effects on, 1250 management, 684 2002 SUBJECT INDEX of orlistat in obese type 2 diabetes, 303, 1899 coronary heart disease in, obesity and, in prevention of of screening for microalbuminuria, in type 2 women, 1142 behavioral science in, 599 diabetes, 2103 C-peptide levels in Ethiopians with, 453 evidence-based nutrition for, 148, 1256 of self-monitoring of blood glucose, 1244 C-reactive protein and, 2016 ADA position statement, 202, 1263, of severe hypoglycemia, 2109 religious attendance and, 1172 $50 of type 2 diabetes complications, in U.S., 476 diagnosis of primary, target population for, 2098 C-peptide ADA Committee report, S5 prevention of influenza and pneumococcal basal and postglucagon levels, in Ethiopians laboratory analysis in, ADA position disease in, ADA position statement, with diabetes, 453 statement, 750 $117 and glucose metabolism, in type 1 diabetes, dobutamine-atropine stress imaging in, 1637 preventive foot care in, ADA position 1096 dyslipidemia in, management of, ADA statement, S69 C-reactive protein position statement, S74 remnant lipoproteins in, 989 and carotid atherosclerosis in type 1 diabetes, E. coli adherence to, 1405 risk of 1432 economic costs of, in Canada, 1303 adiposity-related, reduction by lifestyle and coronary artery calcification, in type 1 erectile dysfunction in, 1458 modification, in Japanese Americans diabetes, 1813 tadalafil effects on, 2159 with impaired glucose tolerance, and insulin resistance in thalassemia minor evidence-based nutrition for, 148, 1256 1504 and family history of diabetes, 1480 ADA position statement, 202, 1263, S50 birthweight and, 1886 and metabolic syndrome, 2016 expenditures and depression in, +64 screening for and P. gingivalis infection, in Japanese type 2 falls risk in, in older women, 1749 ADA position statement, S21 diabetes, 1888 gestational. see Gestational diabetes cardiovascular risk profile of patients plasma levels during glucocorticoid therapy, glimepiride identified by, 1784 losartan effects on, in type 2 diabetes with for, 2359 multivariate logistic regression equation microalbuminuria, 1254 glycemia in, tests of, ADA position statement, for, 1999 postischemic microcirculatory blood flow S97 population-based stepwise, 1784 and, in type | diabetes, 802 HDL cholesterol in, direct measurement of, and quality of life, 1022, 1893 and religious attendance, 1172 1914 test performance, 413 CSIl. see Continuous subcutaneous insulin health-related quality of life in, value of, socioeconomic aspects of, ADA 61st infusion 2238 Scientific Session, 1085 Culturally competent self-management with HIV, pulmonary mucormycosis in, 2105 in state capitals, 2367 education, for Mexican Americans, 259 hospital admission guidelines for, ADA supraspinatus tendon thickness in, 408 Cyclosporin, and 1A-2 antibodies, in type 1 position statement, $109 thalassemia minor and family history of, C- diabetes, 1192 hyperglycemic crisis in, ADA position reactive protein and insulin resistance Cystatin C, GFR estimation with, in type 1 statement, $100 diabetes, 2004 hypertension with in, 1480 TV news coverage of, 607 ACE inhibitors for, 1488 D prevalence of, 2107 type 1. see Type 1 diabetes type 2. see Type 2 diabetes Day care settings, diabetes care in, ADA treatment of, 134 ventricular repolarization in, cardiac position statement, $122 ADA position statement, 199, S71 neuropathy and, 918 DCCT. see Diabetes Control and Complications immunization in, ADA position statement, vitamin E effects in, 1919 Trial $117 vitreous fluid somatostatin-like Denmark, childhood type | diabetes incidence incidence of immunoreactivity deficit in, 2282 in, 2197 from administrative data, in Ontario, 512 Diabetes Atorvastatin Lipid Intervention (DALI) Depression in American Indians, 49 Study among partners of patients with type 2 fiber intake and glycemic index and, 1715 atorvastatin effects on cognitive function and diabetes, 1564 lifestyle intervention for Native American diabetic dyslipidemia, 1250 expenditures and, 464 adults with, 78 Diabetes lipid-lowering drug-treated, Cockcroft’s endothelial function in type 2 diabetes, 1211 adiposity and, different racial groups, 2360 formula for GFR estimation of in, 2106 Diabetes camps, management of diabetes at, adult-onset, with GAD autoantibodies lower extremity function in peripheral artery ADA position statement, $127 clinical heterogeneity of, 2363 disease with and without, 113 Diabetes care. see also Self-management in Japan, 2364 maternal, in HNF-la@ mutation carriers, 2287 access to, private health insurance and, in in Japan, 995 maturity-onset. see Maturity-onset diabetes Medicare patients, 405 antihypertensive therapy in, 2107 mitochondrial for children in school and day care setting, aspirin therapy in, 965 associated with tRNA mutation ADA position statement, $122 ADA position statement, S78 GAD antibody in, 1097 co-management care, 1657 autoimmune, latent, insulin requirements, lipoma and sensory neuropathy in, community interventions, 941 1662 407 community-based, Mayo Health System biceps tendon thickness in, 408 heart rate variability in, 2308 Diabetes Translation Project, 1952 cardiovascular risk factors in mortality in complementary and alternative medicine use, in American Indians and Alaska Natives, all-cause and cardiovascular, 1557 324 279 cause-specific, 43 concurrent, ADA position statement, $130 control of, 718 in elderly, +71 in correctional institutions, ADA position classification of prediction of, with stress statement, $120 ADA Committee report, $5 echocardiography, 1042 at diabetes camps, ADA position statement, ADA vs. WHO, 951 with peripheral neuropathy, walking strategy $127 combination metformin and dipeptidyl in, 1451 evidence-based nutrition for, 148, 1256 peptidase IV inhibitors for, 1490 population-based study in Turkey, 1551 ADA position statement, 202, 1263, $50 complications of posttransplantation, 583, 1667 HMO-sponsored management, short-term epidemiology of, ADA 61st Scientific prevalence of savings and quality improvement Session, 924 from administrative data, in Ontario, 512 associated with, 684 specialist care and incidence of, 1584 in Australia, 829 laboratory analysis in, ADA position coronary calcium in, 696 in Tonga, 1378 statement, 750 2002 SUBJECT INDEX in managed care, Translating Research Into forefoot-to-rearfoot plantar pressure ratio in, Drinking water, and childhood-onset type 1 Action for Diabetes (TRIAD) study, 386 1066 diabetes, 1534 medical nutrition therapy, evidence for, 608 peripheral, fidarestat for, efficacy of, 413 Drug adherence, metabolic control and, 1015 nutritional management in Northern recurrent and fatal hypothermia in, 2108 Drugs. see also specific drugs by name Tanzania, 1486 treatment of, anticonvulsant hypersensitivity insulinotropic, effects on plasma insulin outpatient, and serum lipids, in urban syndrome with eosinophilia in, 1099 levels, 1271 African-Americans, 9 Diabetic polyneuropathy Dutch, multiethnic, determinants of mild planned, Mayo Health System Diabetes carpal tunnel syndrome in, 565, 2362 gestational hyperglycemia and gestational Translation Project, 1952 Clinical Scoring System (CSS) for, validation diabetes mellitus in, 72 preconception, ADA position statement, S82 of, 2048 Dutch primary health care, foot problems primary care, improving, 1946 Diabetic retinopathy related to type 2 diabetes in, 570 specialist, and incidence of diabetes ADA position statement, S90 Dwarfism, diabetic, GERD and progressive complications, 1584 GDNF receptors in, 1060 nephropathy after glycemic control standards of, ADA position statement, 213, and kidney function in type 2 diabetes, 2026 improvement in, in adolescent, 401 $33 pancreas transplantation and, 2358 Dysglycemia screening tests, +13 state differences in, 2230 proliferative Dyslipidemia subspecialist, 1654 development of, 2282 diabetic third-party reimbursement for, ADA position risk factors for, in type 1 diabetes, 798 atorvastatin effects on, 1250 statement, $134 vitreous placenta growth factor and VEGF new strategies for treatment of, 1237 treatment satisfaction, health-related quality levels in, 2352 management of, ADA position statement, S74 of life and, in Dutch patients with type 2 vitreous tenascin-C levels in, 1899 diabetes, +58 screening for, 1477 E for uninsured patients in rural areas, 319 teleophthalmology and, 1384 Eating behavior unproven therapies, ADA position statement, Diet among adolescents with type 1 diabetes, $133 ADA Dietary Guidelines, 1262 1289 in U.S. vs Canada, 1149 chicken-based, and microalbuminuria, in disordered, personal control and, in female Diabetes Care, 1 type 2 diabetes, 645 adolescent type 1 diabetes, 1987 Point-Counterpoint, 1879 combined with voglibose or glyburide, effects Echocardiography, stress Diabetes Control and Complications Trial on abdominal fat and metabolic dobutamine, for detection of CAD in type 2 (DCCT) abnormalities, in type 2 diabetes, 658 diabetes, 1659 glucose profiles and HbA, in, 275 energy-restrictive prediction of death with, in diabetes, 1042 implications of, ADA position statement, S25 effects on weight loss and energy Edema “Diabetes lipidus,” 1474 expenditure, in type 2 diabetes, 652 angioneurotic, with pioglitazone, 405 Diabetes Outcomes in Veterans Study, blood and metabolic risk factors, in obese macular glucose testing strategies, 1744 women, 431 blood-retinal barrier transport in, in type 2 Diabetes Prevention Program (DPP) and exercise, in type 2 diabetes, 1722 diabetes, 1248 body mass index correlates, 1992 gluten-free, and glycemic control, in type 1 and vascular hyperpermeability in type 2 lifestyle intervention, 2165 diabetes and celiac disease, 1117 diabetes with retinopathy, 2328 results of, impact in U.S., 1940 high-protein, in type 2 diabetes, 425 Education “Diabetes proteinus,” 1474 group vs. individual, 269 low-glycemic index, and total fat mass, in Diabetes Quality Improvement Project (DQIP), self-management, 2116 men, 822 249 culturally competent, for Mexican low-sodium, losartan interactions, in type 2 Diabetic dwarfism, GERD and progressive Americans, 259 diabetes, 663 nephropathy after glycemic control long-term effects on glycemic control, in Mediterranean, glycemia and HbA,- in, 1896 improvement in, in adolescent, 401 type 2 diabetes, 2115 staging patterns to reduce diabetes risk in Diabetic dyslipidemia national standards for, $140 atorvastatin effects on, 1250 African-American women, 809 third-party reimbursement for, ADA treatment of, new strategies for, 1237 Dietary fat position statement, $134 Diabetic foot, MRI of, 1444, 1905 and type 2 diabetes, 620 for type 2 diabetes, 1159 Diabetic foot ulcers, oxidized regenerated and type 2 diabetes risk in men, 417 EHIME Study, adult-onset diabetes with GAD cellulose and collagen composite for, 1892 Dietary fatty acid, and insulin sensitivity, 1283 autoantibodies in, 995 Diabetic gastropathy, sildenafil effects on, 1888 Dietary gluten, and type 1 diabetes Elderly Diabetic ketoacidosis autoantibodies in high-risk subjects, 1111 with brittle diabetes, continuous hospitalization for, in Ontario children, 1591 Digital retinal imaging, and diabetic subcutaneous insulin infusion therapy resistant, somatostatin therapy for, 629 retinopathy, 1384 for, long-term follow-up, 402 severe, alkali therapy in, 2113 Dipeptidyl peptidase IV, inhibition of, for type diabetes-related morbidity and mortality in, with tacrolimus, insulin independence after, 2 diabetes, 869 471 1664 Dipeptidy! peptidase IV inhibitors, combined inpatient Medicare costs, in Texas, 1958 Diabetic mastopathy, 120 with metformin, for diabetes, 1490 with NGT, IGT, or type 2 diabetes, Diabetic muscle infarction, 1895 Direct homogeneous assay, for HDL hemostatic factors in, 1340 Diabetic nephropathy cholesterol, in diabetes, 1914 with type 2 diabetes, resistance exercise Disability ADA position statement, S85 training for glycemic control in, 2335 circulating MCP-1 and, 1829 functional, in older women with diabetes, 61 Electrocardiography microalbuminuria and, 406 lower extremity, 678 Q-T interval dispersion, in type 1 diabetes, proteinuria and homocysteine in, 2037 Disordered eating, personal control and, in 702 renin-angiotensin system blockade in, dual, female adolescent type 1 diabetes, 1987 ST-segment elevation myocardial infarction, 95 Dobutamine stress echocardiography, for 1890 risk factors for, type 1 diabetes, 859 detection of CAD in type 2 diabetes, 1659 Electronic management system, Mayo Health Diabetic neuropathy Dobutamine-atropine stress myocardial System Diabetes Translation Project, 1952 auditory brainstem function impairment in, perfusion imaging, prognostic value in ELISPOT assay, GAD65-reactive T-cell 631 diabetes, 1637 detection by, in type 1 diabetes, 1390 chronic painful, isosorbide dinitrate spray Drinking, and atherosclerosis, in type 2 Employer-sponsored health insurance, 1964 treatment of, 1699 diabetes, 1223 Employment 2002 SUBJECT INDEX hypoglycemia and, ADA position statement, Expenditures. see also Cost-benefit analysis Fetal overnutrition, and dysregulation of $132 and depression, 464 adipoinsular axis, in Polynesians, 1539 productivity and medical costs of diabetes, External pump infusion, subcutaneous, Fiber intake, and glycemic index and diabetes 23 antigenicity of insulin via, 84 incidence, 1715 Endothelial dysfunction Fidarestat, efficacy for diabetic peripheral advanced glycation end products and, 1055 neuropathy, +13 F gestational diabetes and, 560 Filipina-American women, type 2 diabetes and Endothelial function F, isoprostanes, plasma, 537 metabolic syndrome in, 494 sildenafil and, in type 2 diabetes, 1336 F,,, isoprostanes, and acute hyperglycemia, in Finger in type 2 diabetes, 1211 type 2 diabetes, 537 capillary glucose and Het from tip of, 337 Endothelial vasodilation, statin effects on, in Fall-related fractures, 1983 capillary glucose levels at, 961 type 2 diabetes, 1242 Falls Finger sepsis, with reuse of lancets, 1103 End-stage renal failure, kidney-pancreas incidence of, 1983 First-degree relatives transplantation and coronary risk factors for, 1983 of type 2 diabetes patients, insulin and atherosclerosis progression in, 906 risk of, in older women with diabetes, 1749 amylin release in, 292 Cnergy expenditure, protein and, in type 2 Family history of young-onset type 2 diabetes patients, diabetes, 652 of diabetes, thalassemia minor and, C- diabetes risk in, 636 Energy metabolism, in heart transplant reactive protein and insulin resistance Fish oil supplementation, and lipoprotein recipients, 530 in, 1480 subclasses, in type 2 diabetes, 1704 Energy-restrictive diet of type 2 diabetes, visceral fat and insulin Fitness, cardiorespiratory, and metabolic effects on weight loss and energy sensitivity in obese Hispanic children syndrome, 1612 expenditure, in type 2 diabetes, 652 with, 1631 Food synergy, 1652 and metabolic risk factors, in obese women, Fasting, and plasma glucose values, 2112 Foot care, preventive, ADA position statement, 431 Fasting hyperglycemia S69 Enteric tube feeding, continuous, insulin and cardiovascular disease risk, 1845 Foot problems glargine in, 1889 insulin therapy for gestational diabetes with, case definition for, in hospitalized patients, Eosinophilia, anticonvulsant hypersensitivity 1261 630 syndrome with, 1099 and postprandial hyperglycemia, 1247 MRI of, 1444, 1905 Erectile dysfunction Fasting insulin prediction of, 2010 in diabetes, 1458 in children, 2081 related to type 2 diabetes, in Dutch primary tadalafil effects on, 2159 ethnicity and, 1351 health care, 570 and quality of life, 284 Fasting plasma glucose Foot ulcers Escherichia coli, adherence to uroepithelial cells, combined with HbA, ,., for diabetes screening diabetic neuropathic, 1835 1405 in American Indians, 1365 falls and fall-related fractures with, 1983 Estrogen, effects on glucose, insulin, and type 2 and outcome, in type 2 diabetes, 1410 forefoot-to-rearfoot plantar pressure ratio diabetes risk, in American Indian Fasting serum insulin, and race, 1358 and, 1066 postmenopausal women, 500 Fat oxidized regenerated cellulose and collagen Ethiopians with diabetes, basal and abdominal composite for, 1892 postglucagon C-peptide levels in, 453 combination diet and voglibose or in type 2 diabetes, in Dutch primary health Ethnicity glyburide and, in type 2 diabetes, 658 care, 370 and body mass index and fasting insulin, weight loss and, in obese women, 431 Forearm 1351 body fat distribution, improvement by capillary glucose and Het of, 337 insulin resistance across, 2184, 2350 lifestyle modification, in Japanese capillary glucose levels at, 961 EURODIAB IDDM Complications Study Group, Americans with impaired glucose Forefoot-to-rearfoot plantar pressure ratio Q-T interval dispersion in type | diabetes, tolerance, 1504 in diabetic neuropathy, 1066 702 dietary and ulceration, 1066 EURODIAB Prospective Complications Study, and type 2 diabetes, 620 Fractures, fall-related, 1983 TGF-B1, Amadori albumin, and and type 2 diabetes risk in men, 417 Framingham Offspring Study complications of type 1 diabetes, 2320 intermuscular. weight loss and, in obese fasting and postchallenge glycemia and Europe, early growth and childhood type | women, 431 cardiovascular disease risk, 1845 diabetes in, 1755 total fat mass, low-glycemic index diet and, glycemia and microalbuminuria, 977 European Association for the Study of Diabetes in men, 822 remnant lipoproteins in diabetes, 989 (EASD), 2001 meeting, 1229 visceral, and insulin sensitivity, in obese subclinical coronary atherosclerosis in type 2 European-Americans, with diabetes, partner Hispanic children, 1631 diabetes, 1313 depression and anxiety among, 1564 Fatty acid, dietary, and insulin sensitivity, 1283 France, insulin resistance syndrome in, 1371 Evidence-based nutrition, for diabetes Feeding, thermic effects of, in type 2 diabetes, Fructose, blood and urine levels, 353 treatment and prevention, 148, 1256 652 Fulminant type | diabetes ADA position statement, 202, 1263, S50 Females. see also Women with autoimmunity, 1482 Evoked potentials with type | diabetes, personal control and with elevated Rh factor and TSH receptor somatosensory, pain, with small-fiber disordered eating in, 1987 antibody, 935 neuropathy, 2355 with type | diabetes and bulimia nervosa, with Graves’ disease, 1894 visual, impairment of, 1661 classification according to rurging, 1571 with insulin deficiency, in Japanese children, Exercise Fenofibrate 2353 diabetes mellitus and, ADA position combined with atorvastatin, in type 2 with T-cell-mediated autoimmunity, 635 statement, S64 diabetes, 1198 Functional disability, in older women with diet and, in type 2 diabetes, 1722 effects on plasma triglycerides and LDL diabetes, 61 Qi-gong relaxation, and type 2 diabetes particle diameter, in type 2 diabetes, control, 241 627 resistance training, and glycemic control, in Ferritin, high-ferritin type 2 diabetes, blood G older adults with type 2 diabetes, 1729, letting in, 2249 2335 Fetal growth Gastric band surgery, laparoscopic adjustable, and vascular function, in type | diabetes, and gestational diabetes therapy, 1261 358 1795 and pregestational diabetic pregnancy, 1681 Gastric emptying, in type 1 diabetes, 912 2002 SUBJECT INDEX Gastroesophageal reflux disease, after glycemic bedside, in hospitals, ADA position in pregnancy, 2104 control improvement, in adolescent statement, $110 strategies for, in type 2 diabetes, 1744 diabetic dwarfism, 401 and glycemic control, in type 2 diabetes, in type 2 diabetes, 1256 Gastropathy, diabetic, sildenafil effects on, 245 value of, 1255 1888 noninvasive, 2268 subcutaneous Gender differences, in oxidative stress, in type 1 with optical coherence tomography, 2263 continuous, 347 diabetes, 370 self-monitoring microdialysis vs. intracorporeal, +10 Gene polymorphisms, ACE, and metabolic costs of, 1244 whole-blood, at alternative sites, 337 syndrome meal-related, in type 2 diabetes, 1928 Glucose tolerance in Brazilian type 2 diabetes, 2365 in pregnancy, 2104 impaired in Chinese type 2 diabetes, 1002, 2366 in type 2 diabetes, 1256 adiposity-related diabetes risk in, Genotype value of, 1255 reduction by lifestyle modification, in mitochondrial, associated with autoimmune- capillary Japanese Americans, 1504 related type 1 diabetes, 2106 from finger, forearm, and thigh, 961 diabetes and, among Inuit, 1766 type | diabetes-associated HLA, screening from fingertip and forearm, 337 hemostatic factors in elderly with, 1340 for, in gestational diabetes, 68 diabetic breast-milk and, 16 nateglinide effects in, 2141 vitamin D receptor, and age of onset in endogenous output of, intravenous glargine during pregnancy, in Tianjin, China, 1619 juvenile type | diabetes, in Japanese, vs regular insulin effects on, 1597 prevalence of, in Australia, 829 1244 estrogen and, in American Indian normal, hemostatic factors in elderly with, Gestational diabetes postmenopausal women, 500 1340 in Aboriginal women, 487 homeostasis of, in SUR1 mutation carriers, obesity and, in family with mutant insulin ADA position statement, S94 receptor, 1484 determinants of, in Dutch multiethnic metabolism of - oral glucose tolerance test, two-hour 75-g, cohort, 72 caiapo and, in type 2 diabetes, 239 early in pregnancy, 803 and endothelial dysfunction, 560 C-peptide and, in type 1 diabetes, 1096 Glucose tolerance test, value of, 1880, 1883 with fasting hyperglycemia, insulin therapy glimepride effects on, in type 2 diabetes, a-Glucosidase inhibitor, oral antidiabetic for, 1261 2065 interactions, 247 fetal overnutrition in, and dysregulation of hormone replacement therapy and, in Glutamic acid decarboxylase 65 adipoinsular axis, in Polynesians, 1539 postmenopausal women, 1675 GAD65 antibody epitope patterns of type 1.5 and low maternal birth weight, 1761 hostility, race, and, 835 diabetes, 1481 pregestational diabetic pregnancy, fetal oral contraceptives, in young adult women, GAD65-reactive T-cell detection in type 1 growth spurt and, 168] 1027 diabetes, 1390 prevalence of, by diagnostic criteria, 1625 plasma levels Glutamic acid decarboxylase antibodies screening for, in Chinese women, 796 Carpenter and Coustan thresholds, in mitochondrial diabetes associated with screening for MODY mutations in, 68 prevalence of gestational diabetes by, tRNA mutation, 1097 in single-gravidity women in Tianjin City, 1625 screening for, in gestational diabetes, 68 China, 847 fasting, 2112 Glutamic acid decarboxylase autoantibodies, and type 2 diabetes incidence, 1862 combined with HbA, .., for diabetes adult-onset diabetes with Gestational hyperglycemia, mild, determinants screening in American Indians, 1365 clinical heterogeneity of, 2363 of, in Dutch multiethnic cohort, 72 and outcome, in type 2 diabetes, in Japan, 2364 Glial cell line-derived neurotrophic factor 1410 in Japan, 995 receptors, in diabetic retinopathy, 1060 and HbA, ., 275 Gluten, dietary, and type 1 diabetes Glimepiride sensor levels and, 889 autoantibodies in high-risk subjects, 1111 combined with rosiglitazone plus metformin, sensor levels Gluten-free diet, and glycemic control, in type in type 2 diabetes, 1251 and plasma glucose level, 889 1 diabetes and celiac disease, 1117 for diabetes mellitus during glucocorticoid reproducibility of, 1185 Glyburide therapy, 2359 splanchnic uptake, in type 1 diabetes, 2042 cardiovascular effects in type 2 diabetes, effects on glucose turnover, in type 2 Glucose counterregulatory hormones, glyburide 2058 diabetes, 2065 and, 107 combined with diet, effects on abdominal fat effects on insulin action, in skeletal muscie, Glucose monitoring and metabolic abnormalities, in type 2 2129 alternative-site, at abdomen, 2114 diabetes, 658 effects on insulin secretion, in type 2 at arm, 639, 956 effects in type 2 diabetes, 1737 diabetes, 1607 barriers to, in multiethnic community, 1772 and glucose counterregulatory hormones, Glipizide GITS, combined with metformin, in bedside, in hospitals, ADA position 107 type 2 diabetes, 2123 statement, $110 and pancreatitis, 292 Glomerular filtration rate continuous, 1185 Glycemia Cockcroft's formula estimation of, in lipid- evaluation of, 1603 and HbA, , lowering drug-treated diabetes, 2106 glucose area under profiles obtained with, in Mediterranean diet, 1896 cystatin C measure of, in type 1 diabetes, and HbA,¢ , in pediatric type 1 in type 1 diabetes, 1100 diabetes, 1840 and microalbuminuria, 977 decline in type 2 diabetes, 2026 Continuous Glucose Monitoring System postchallenge, and cardiovascular disease Glucocorticoid therapy, glimepiride for diabetes (CGMS) (Medtronic), nocturnal risk, 1845 during, 2359 hypoglycemia recording by, in type 1 tests of, ADA position statement, S97 Glucose diabetes, 1499 Glycemic control absorption of, small bowel motility and, continuous subcutaneous, 347 cigarette smoking and, in diabetes, 796 1857 and glycemic control, in type 2 diabetes, 245 failure of, in type 2 diabetes, 737 blood intermittent vs continuous, 1603 GERD and progressive nephropathy after distribution of, bimodality of, 2212 noninvasive, 2268 improvement oi, in adolescent diabetic third-trimester maternal, in nondiabetic with optical coherence tomography, 2263 dwarfism, 401 pregnancies, 939, 1104 self-monitoring gluten-free diet and, in type 1 diabetes and variability of, in type 1 diabetes, 2256 costs of, 1244 celiac disease, 1117 blood glucose monitoring evaluation of, 1603 high-protein diet and, in type 2 diabetes, 425 alternative-site, at abdomen, 2114 meal-related, in type 2 diabetes, 1928 hormone replacement therapy and, 246 2002 SUBJECT INDEX long-term, stress management and, 30 Heart disease HOME-trial (Hyperinsulinemia: the Outcome and PAI-1, in type 2 diabetes, 2123 coronary of its Metabolic Effects), 2133 poor, insulin-pump therapy for, in type 1 risk factors for, in type 2 diabetes, 1522 Homocysteine, plasma levels diabetes, 2074 screening for, in type 2 diabetes, 2032 in microalbuminuria with type 2 diabetes, postprandial, with biphasic insulin aspart, obesity and, in diabetic women, 1142 632 883 rosiglitazone vs glyburide effects on, in type total, proteinuria and, in type 2 diabetic resistance training for, in older adults with 2 diabetes, 2058 nephropathy, 2037 type 2 diabetes, 1729, 2335 Heart Outcomes Prevention Evaluation (HOPE) Honolulu Heart Program, diabetes and total rosiglitazone vs glyburide effects on, in type trial, vitamin E effects in diabetes, 1919 and cardiovascular mortality in Japanese- 2 diabetes, 2058 Heart rate American men, 951 self-management education and, in type 2 in high normal blood pressure, 971 Hoorn Study, blood pressure, lipids, obesity, diabetes, 1159, 2115 variability of, in mitochondrial diabetes, and retinopathy, 1320 wheat bran and, in type 2 diabetes, 1522 2308 Hormone replacement therapy Glycemic index, fiber intake and diabetes Heart transplant recipients, energy metabolism and glycemic control, 246 incidence and, 1715 in, 530 in postmenopausal women, 1876 Glycogen, insulin-stimulated synthesis of, Helicobacter pylori infection, re-infection in type and insulin resistance, 127 glimepiride effects on, in skeletal muscle, 1 diabetes, 1485 and lipid and glucose metabolism, 1675 2129 Hematocrit, capillary, from fingertip and in women with type 2 diabetes, 246 Glycotoxins, 1898 forearm, 337 Hormones, glucose counterregulatory, Grain, whole, 1652 glyburide and, 107 Hemochromatosis C282Y and H63D mutations, Graves’ disease, fulminant type | diabetes with, in type 2 diabetes, 2112 Hospitalization 1894 Hemoglobin A,, admission guidelines for diabetes mellitus, Greenland, diabetes and impaired glucose additional NPH insulin effects on, 712 ADA position statement, S109 tolerance among Inuit, 1766 in American Indian/Alaska Native adults, bedside blood glucose monitoring, ADA Group diabetes education 2178 position statement, $110 assessment of, 269 in children and young adults, in U.S., 1326 for diabetic ketoacidosis, in Ontario children, culturally competent, for Mexican Americans, computer-generated personalized goals and, 1591 259 foot complications in, case definition for, 630 2 Growth fasting plasma glucose plus, for diabetes inpatient Medicare costs, among Texas early, and childhood type | diabetes, in elderly, 1958 screening in American Indians, 1365 European populations, 1755 Hostility, and glucose metabolism, 835 glucose area under CGMS profiles and, 1840 fetal Human immunodeficiency virus infection glycemia and and gestational diabetes therapy, 1261 metabolic syndrome in, 1253 in Mediterranean diet, 1896 and pregestational diabetic pregnancy, pulmonary mucormycosis in diabetes with, in type | diabetes, 1100 1681 2105 interpersonal predictors of, 731 Guidelines Human insulin ADA Dietary Guidelines, 1262 plasma glucose and, 275 allergy to, continuous subcutaneous insulin scale of reported results, 2110 adherence to infusion for, 634 in pharmacist-managed diabetes clinics, Hemostatic factors regular, and endogenous glucose output, 1479 in elderly with NGT, IGT, or type 2 diabetes, 1597 by primary care physicians, 1946 1340 subcutaneous, leukocytoclastic vasculitis comparative analysis of, 1933 and insulin resistance syndrome, in induced by, in type | diabetes and hospital admission, ADA position statement, Southwestern France, 1371 essential thrombocytopenia, 242 S109 Hepatic function, in type 2 diabetes, evaluation Human lymphocyte antigen, class II genes, in during clinical trials, 815 Japanese GADab* non-insulin deficiency H Hepatitis C infection, chronic, serum leptin and 995 insulin sensitivity in, 937, 1495, 1900 Health, Aging, and Body Composition Study, Human lymphocyte antigen genotype, type | 413 Hepatocyte nuclear factor-la diabetes-associated, screening for, in Health care G319S mutation, in Canadian aboriginal gestational diabetes, 68 and depression, 464 youth with type 2 diabetes, 2202 Human lymphocyte antigen-DQ, in in Medicare patients, 405 mutation carriers autoantibody-negative rapid-onset type 1 Health care institutions, translation of the intrauterine hyperglycemia in, 2287 diabetes, 2302 diabetes nutrition recommendations for, MODY3 in, 2292 HyperapoB, hypertriglyceridemic, in type 2 S61 Hepatotoxicity, of rosiglitazone, in type 2 diabetes, 579 Health care providers, and diabetes diabetes, 815 Hyperglycemia complications, 1584 High-density lipoprotein, fish oil vs corn oil acute, F,,, isoprostanes and, in type 2 Health insurance supplementation effects on, in type 2 diabetes, 537 employer-sponsored, 1964 diabetes, 1704 fasting private, 405 High-density lipoprotein cholesterol, direct and cardiovascular disease risk, 1845 Health maintenance organization measurement of, in diabetes, 1914 insulin therapy for gestational diabetes (HMO)-sponsored diabetes management, Hispanic children with, 1261 short-term savings and quality insulin resistance in, 2184, 2350 and postprandial hyperglycemia, 1247 improvement associated with, 684 obese, visceral fat and insulin sensitivity in, gestational, mild, determinants of, in Dutch Health policy, Diabetes Quality Improvement 1631 multiethnic cohort, 72 Project (DQIP), 249 “Hispanic Paradox,” evidence against, 1557 intrauterine, in HNF-la mutation carriers, Health-related quality of life Hoechst 21PH insulin, antigenicity of, 84 2287 marital relationship factors and, in diabetes, Home blood pressure measurement, in morning excursions, 737 1154 morning, in type 2 diabetes, 2218 in nitrotyrosine postprandial generation, and type 2 diabetes, in Dutch patients, 458 Homeostasis model assessment 1439 value of, in diabetes, 2238 of insulin resistance, in postmenopausal postchallenge, in U.S. adults with type 2 Healthy women bias, and hormone replacement women, 2022 diabetes, 249 therapy in women with type 2 diabetes, of insulin sensitivity, in kidney-pancreas postprandial 246 transplant recipients, 2207 in adolescents, 1887 2002 SUBJECT INDEX control of, 2147 metabolic syndrome in, 1253 during pregnancy, in type | diabetes, 1095 fasting hyperglycemia and, 1247 pulmonary mucormycosis in diabetes Insulin lispro twin pregnancy and, in multiethnic New with, 2105 vs glargine, 404, 1103 Zealand community, 934 P. gingivalis, C-reactive protein and, in patient administration of, reducing mistakes undiagnosed, prediction of, 984 Japanese type 2 diabetes, 1888 in, 1098 Hyperglycemic crisis, with diabetes mellitus, urinary tract, risk of, diabetes and, in in type | diabetes, 2053 ADA position statement, $100 postmenopausal women, 1778 Insulin receptor substrate IRS-1, Gly972Arg Hyperhomocysteinemia, and risk of Inflammatory markers, and insulin resistance polymorphism, and birth weight, in retinopathy, in type 2 diabetes, 2361 syndrome, in Southwestern France, 1371 Brazilian newborns, 550 Hyperinsulinemia Influenza, prevention of, ADA position Insulin receptors, mutation of, obesity and acanthosis nigricans and, in Cherokee statement, $117 glucose tolerance in family with, 1484 Indians, 1009 Infratec, Inc., noninvasive blood glucose Insulin resistance HOME-trial (Hyperinsulinemia: the Outcome monitor, 2268 in African-American and Hispanic children, of its Metabolic Effects), 2133 Inhaled insulin, dose reproducibility of, 2276 2184, 2350 plasma glucose levels in, sensor levels and, Injection insulin therapy caffeine and, 399 889 indications for, 2100 and cardiovascular disease, 1135, 1177 Hyperlipidemia, combined, combination intensive, in type 1 diabetes, 2074 in children, E1 atorvastatin and fenofibrate in type 2 Insulin conjugated linoleic acid and, in obese men diabetes with, 1198 and alveolar-capillary membrane gas with metabolic syndrome, 1516 Hyperpermeability, vascular, macular edema conductance, in type 2 diabetes, 1802 coronary artery calcification in, 1313 and, in type 2 diabetes with retinopathy, antigenicity of, peritoneal vs subcutaneous, C-reactive protein and, in thalassemia minor 2328 84 and family history of diabetes, 1480 Hypersensitivity, anticonvulsant and central pressure, in type 2 diabetes, 2314 homeostasis model assessment-derived, in hypersensitivity syndrome with co-release of amylin and, in first-degree postmenopausal women, 2022 eosinophilia, in treatment of diabetic relatives, 292 hormone replacement therapy and, in post neuropathy, 1099 deficiency of, fulminant-onset idiopathic type menopausal women, 127 Hypertension 1 diabetes with, in Japanese children, measures of, in kidney-pancreas control of cardiovascular risk factors in, 718 2353 transplantation, 2207 with diabetes effects in children, fasting indices of, 2081 in obesity ACE inhibitors for, 1488 effects in heart transplantation, 530 acanthosis nigricans and, in children, 2353 prevalence of, 2107 estrogen and, in American Indian hypertension and, ASH and ADA annual treatment of, 134 postmenopausal women, 500 meetings, 2088 ADA position statement, 199, S71 fasting, ethnicity and, 1351 after renal transplantation, 1259, 1260 obesity and insulin resistance and, ASH and human in twins, 2191 ADA annual meetings, 2088 allergy to, continuous subcutaneous Hypertriglyceridemic hyperapoB, in type 2 insulin infusion for, 634 Insulin Resistance and Atherosclerosis Study diabetes, 579 subcutaneous, leukocytoclastic vasculitis (IRAS) Hypoglycemia induced by, in type | diabetes and alcohol, insulin sensitivity, diabetes, and additional NPH insulin effects on, 712 essential thrombocytopenia, 242 CVD, 1425 from clarithromycin-sulfonylurea drug long-acting, 1666 vitamin E and type 2 diabetes incidence, interactions, 1659 oral contraceptives, in young adult women, 2172 detection of, by glucose monitoring at arm, 1027 Insulin resistance syndrome 639 plasma levels, insulinotropic drug effects on, inflammatory and hemostatic markers and, in and employmenvlicensure, ADA position 1271 Southwestern France, 1371 statement, $132 regular, and endogenous glucose output, neighborhood characteristics and nocturnal, recording, in controlled type 1 1597 components of, in young adults, 1976 diabetes, 1499 requirement for, in latent autoimmune Insulin secretagogue therapy plasma glucose levels in, sensor levels and, diabetes of the adult, 1662 new drugs, 1472 889 secretion of short-acting, for postprandial hyperglycemia, severe, incidence and costs of, 2109 glimepride effects on, in type 2 diabetes, 2147 and type 1 diabetic pregnancy, 554 1607 for type 2 diabetes, optimizing, 342 Hypothermia, recurrent and fatal, in diabetic pioglitazone dose-response effects on, in Insulin sensitivity neuropathy, 2108 type 2 diabetes, 517 and alcohol consumption and carotid serum, and race, 1358 atherosclerosis, 1425 t -stimulated glycogen synthesis, glimepiride and B-cell function, in polycystic ovary IA-2 antibodies, cyclosporin and, in type 1 effects on, in skeletal muscle, 2129 syndrome, 1217 diabetes, 1192 Insulin analogs, rapid-acting, concurrent caffeine and, 364 Imaging measurement of insulin and, 1049 dietary fatty acid effects on, 1283 digital retinal, and diabetic retinopathy, 1384 Insulin aspart homeostasis model assessment of (HOMA- magnetic resonance, of diabetic neuropathic biphasic, postprandial glycemic control with, IS), in kidney-pancreas transplant foot, 1444, 1905 883 recipients, 2207 myocardial perfusion, prognostic value in in CSII, for type 1 diabetes, 439 lifestyle intervention for improvement of, 445 diabetes, 1637 immune responses to, 876 in Mexican Americans from San Antonio vs Immunization, ADA position statement, $117 infusion site lifetime, 1663 Mexicans from Mexico City, 937 Immunogenicity, of Asp, 876 in type 1 diabetes, 2053 pioglitazone dose-response effects on, in type Implantable intraperitoneal pump, antigenicity Insulin glargine (Lantus) 2 diabetes, 517 of insulin via, 84 in continuous enteric tube feeding, 1889 prediction of, in prepubertal and early Infection intravenous, and endogenous glucose output, pubertal children, 1203 H. pylori, re-infection in type 1 diabetes, 1597 Quantitative Insulin Sensitivity Check Index 1485 vs lispro, 404, 1103 (QUICKI) hepatitis C, chronic, serum leptin and insulin once-daily dosing, 1479 in kidney-pancreas transplant recipients, sensitivity in, 937, 1495, 1900 patient administration of, reducing mistakes 2207 HIV in, 1098 in obese patients, 642 2002 SUBJECT INDEX serum leptin and, in chronic hepatitis-C Intrauterine hyperglycemia, in HNF-la serum levels, and insulin sensitivity, in infection, 937, 1495, 1900 mutation carriers, 2287 chronic hepatitis-C infection, 937, and type 2 diabetes incidence in San Inuit, diabetes and impaired glucose tolerance 1495, 1900 Antonio, Texas vs Mexico City, Mexico, among, in Greenland, 1766 Lesions, tubulointerstitial, cigarette smoking 938 Ipomoea batatas (caiapo), effects on glucose and, in type 2 diabetes, 1486 visceral fat and, in obese Hispanic children, metabolism and serum cholesterol in type Leukocytoclastic vasculitis, induced by 1631 2 diabetes, 239 subcutaneous human insulin, in type 1 Insulin sensitivity index Irbesartan, and albumin excretion rate, in type diabetes and essential thrombocytopenia, from Japanese type 2 diabetics, 626 2 diabetes, 1909 242 from oral glucose tolerance test, for advanced Ischemia, postischemic microcirculatory blood Licensure, hypoglycemia and, ADA position type 2 diabetes, 1891 flow, and plasma C-reactive protein, in statement, $132 Insulin therapy type | diabetes, 802 Lifestyle intervention addition to oral therapy for type 2 diabetes, Isosorbide dinitrate spray, for chronic painful Diabetes Prevention Program (DPP), 2165 395 diabetic neuropathy, 1699 for insulin sensitivity improvement, 445 addition to sulfonylurea therapy, 330, 1268 for Native American adults with diabetes, 78 administration of J and prevention of type 2 diabetes, 1650 ADA position statement, $112 reduction of adiposity-related diabetes risk patient mistakes in, reducing, 1098 Japanese by, in Japanese Americans with combined with metformin, in type 2 with adult-onset diabetes and GAD impaired glucose tolerance, 1504 diabetes, 2133 autoantibodies, 995 Linoleic acid, conjugated, and insulin combined with metformin vs troglitazone, in children with fulminant-onset idiopathic type resistance, in obese men with metabolic type 2 diabetes, 1691 1 diabetes and insulin deficiency, 2353 syndrome, 1516 continuous subcutaneous infusion with juvenile type 1 diabetes, VDR genotype Lipid profile ADA position statement, $116 and age of onset in, 1244 chicken-based diet and, in type 2 diabetes, for allergy to human insulin, 634 preobesity and metabolic syndrome in, 1252 645 evidence base for, 593 with type 2 diabetes plasma, low-glycemic index and, in men, 822 indications for, 2100 C-reactive protein in, P. gingivalis infection Lipid-lowering drug-treated diabetes, and, 1888 insulin aspart in, for type 1 diabetes, 439 Cockcroft's formula for GFR estimation of insulin sensitivity indexes from, 626 long-term follow-up, in brittle diabetic in, 2106 intima-media thickness in CAD in, 1308 elderly, 402 Lipids Japanese-Americans metformin therapy during, in type | high-protein diet and, in type 2 diabetes, 425 with impaired glucose tolerance, lifestyle diabetes, 2153 metabolism of, hormone replacement therapy modification for reduction of adiposity- in type | diabetes, 2074 and, in postmenopausal women, 1675 related diabetes risk in, 1504 for gestational diabetes with fasting and retinopathy, 1320 men, diabetes and mortality in, 951 hyperglycemia, 1261 serum, outpatient management and, in urban Juvenile diabetes. see Childhood diabetes independence from, after diabetic African-Americans with, 9 ketoacidosis associated with tacrolimus, Lipohypertrophy, in young type 1 diabetes 1664 K patients, 634 inhaled, dose reproducibility of, 2276 Lipoma, in mitochondrial diabetes associated Ketoacidosis, diabetic injection with tRNA mutation, 407 hospitalization for, in Ontario children, 1591 indications for, 2100 Lipoprotein(a), and silent coronary disease in resistant, somatostatin therapy for, 629 intensive, in type 1 diabetes, 2074 type 2 diabetes, 1418 severe, alkali therapy in, 2113 orlistat effects in type 2 diabetes on, 1033, Lipoproteins Kidney function 1495, 2119 chicken-based diet and, in type 2 diabetes, remnant, in diabetes, 989 patient confusion over, 1103 645 subclasses, fish oil vs corn oil pump therapy diabetic retinopathy and proteinuria and, in supplementation effects on, in type 2 antigenicity of insulin via, 84 type 2 diabetes, 2026 diabetes, 1704 evidence base for, 593 outcome in type 2 diabetes, 900 Lispro (Humalog) insulin indications for, 2100 Kidney transplantation, insulin resistance after, vs glargine, 404, 1103 pediatric use of, 1663 1259, 1260 patient administration of, reducing mistakes in type | diabetes, 2074 Kidney-pancreas transplantation in, 1098 retinopathy with, in type 2 diabetes, 381 and coronary artery disease progression, 906 in type 1 diabetes, 2053 subcutaneous infusion, continuous measures of insulin resistance in, 2207 Liver function, in type 2 diabetes, evaluation of, ADA position statement, $116 Koreans, Werner syndrome in, 1483 during clinical trials, 815 for allergy to human insulin, 634 Lobulitis, sclerosing lymphocytic, type 1 evidence base for, 593 diabetes association with, 120 L insulin aspart in, for type 1 diabetes, +39 Logistic regression equation, multivariate, for long-term follow-up, in brittle diabetic Laboratory analysis, ADA position statement, diabetes screening, 1999 elderly, 402 750 Long-term programming, diabetic breast milk metformin therapy during, in type 1 Lancets, finger sepsis with reuse of, 1103 and, 16 diabetes, 2153 Laparoscopic adjustable gastric banding, health Losartan Insulin-like growth factor binding protein-1, outcomes of, 358 low-sodium diet interactions, in type 2 and carotid wall thickness, in type 2 Laser-induced pSEPs, with small-fiber diabetes, 663 diabetes, 1807 neuropathy, 2355 and plasma C-reactive protein levels in type 2 Insulinotropic drugs, effects on plasma insulin Latinos with diabetes, partner depression and diabetes with microalbuminuria, 1254 levels, 1271 anxiety among, 1564 and urinary TGF-B, in type 2 diabetes, 1072 Intermuscular fat, weight loss and, in obese Leisure-time physical activity. see also Exercise; Low-density lipoprotein women, 431 Physical activity fish oil vs corn oil supplementation effects Intracorporeal subcutaneous glucose and metabolic syndrome, 1612 on, in type 2 diabetes, 1704 monitoring, +10 Leptin particle diameter, fenofibrate and, in type 2 Intraperitoneal pump, implantable, antigenicity cord-blood, in newborns of diabetic mothers, diabetes, 627 of insulin via, 84 1886 size, in high normal blood pressure, 971